Publications
152
Citations
2,060
Est. group size
~32
Recurring co-author estimate
Active years
40
Publishing since 1987
Francesca Cottini studies multiple myeloma, a cancer of plasma cells in the bone marrow, focusing on the molecular mechanisms that allow myeloma cells to survive stress and resist treatment, such as DNA damage repair pathways, protein degradation systems, and cell stress responses. Her work spans laboratory studies of drug targets (like Akt, TTK/MPS1, and CREB1 pathways) as well as clinical research on treatment outcomes and biomarkers such as CD56 expression and monoclonal gammopathy conditions. This combination of basic and clinical research aims to identify new therapeutic strategies and improve patient outcomes in myeloma and related blood disorders.
Publication output grew substantially from 2017 through a peak in 2023, then declined somewhat in 2024-2026, though it remains higher than levels seen earlier in the decade.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival
Cell Death and Disease · 2026
- Editorial Expression of Concern: Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers
Nature Medicine · 2026
- Maintenance Therapy and Improved Relapse-Free Survival in Patients with Monoclonal Gammopathy of Renal Significance
Blood Advances · 2026
- Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
eJHaem · 2025
- CD56 expression predicts response to Daratumumab-based regimens
Blood Cancer Journal · 2024
- Real-World Outcomes of Monoclonal Gammopathy of Renal Significance (MGRS) in the Era of Novel Therapies
Blood · 2024
- CREB1 and TXNIP Regulate Autophagy and Unfolded Protein Response in Multiple Myeloma
Blood · 2024
- Understanding DNA Damage Response and DNA Repair in Multiple Myeloma
Cancers · 2023
- A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma
Future Oncology · 2023
- TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma
Haematologica · 2023
- Characterization of monoclonal gammopathy of undetermined significance progression to multiple myeloma through meta-analysis of GEO data
Heliyon · 2023
- To be or not to be: the role of CD56 in multiple myeloma
Oncotarget · 2023
- Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study
Blood · 2023
- Supplementary Methods from Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition
2023
- Supplementary Figure Legends from Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition
2023
- Blood×28
- Journal of Clinical Oncology×6
- Clinical Lymphoma Myeloma & Leukemia×5
- Cancers×3
- Frontiers in Oncology×3
- Rafat Abonour
Medicine · Indiana University
- Mohammad Abu Zaid
Medicine · Indiana University
- Brian A. Walker
Medicine · Indiana University
- Parvathi Sudha
Medicine · Indiana University
- Attaya Suvannasankha
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile